Karxun
2021-03-21
Tell me your opinion about this news...
1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should<blockquote>沃伦·巴菲特和凯西·伍德拥有 1 只共同点,以及他们应该拥有的 1 只股票</blockquote>
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":359959063,"tweetId":"359959063","gmtCreate":1616327269352,"gmtModify":1634526331910,"author":{"id":3557226916148056,"idStr":"3557226916148056","authorId":3557226916148056,"authorIdStr":"3557226916148056","name":"Karxun","avatar":"https://static.tigerbbs.com/87ed84363df8cc411fdf60c3f6eace23","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Tell me your opinion about this news...</p></body></html>","htmlText":"<html><head></head><body><p>Tell me your opinion about this news...</p></body></html>","text":"Tell me your opinion about this news...","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/359959063","repostId":1190757715,"repostType":4,"repost":{"id":"1190757715","kind":"news","pubTimestamp":1616161968,"share":"https://www.laohunote.com/m/news/1190757715?lang=zh_CN&edition=full","pubTime":"2021-03-19 21:52","market":"us","language":"en","title":"1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should<blockquote>沃伦·巴菲特和凯西·伍德拥有 1 只共同点,以及他们应该拥有的 1 只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1190757715","media":"Motley Fool","summary":"It might be a surprise to find out that two investors with virtually opposite approaches -- one who ","content":"<p>It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her outlandishly bullish (and accurate) predictions about \"overvalued\" stocks -- would have the same company in their portfolios. Perhaps the bigger surprise is the stock you might expect them to both own that they don't. Let's take a look at the two companies in question and what these successful investors must see.</p><p><blockquote>人们可能会惊讶地发现,两位持有几乎相反方法的投资者——一位投资于大型、廉价、标志性公司,另一位则因她对“高估”股票的异常乐观(且准确)预测而声名鹊起——他们的投资组合中将有同一家公司。也许更大的惊喜是你可能期望他们都拥有但他们没有的股票。让我们来看看这两家公司,以及这些成功的投资者必须看到什么。</blockquote></p><p><b>The surprising stock they both own</b></p><p><blockquote><b>他们都拥有令人惊讶的股票</b></blockquote></p><p>First, it's doubtful that Warren Buffett actually bought<b>Snowflake</b>(NYSE:SNOW), the cloud data warehouse-as-a-service company. In recent years, lieutenants Todd Combs and Ted Weschler have been making more of the investment decisions, and the $750 million in stock<b>BerkshireHathaway</b>(NYSE:BRK.A)(NYSE:BRK.B)purchased before theinitial public offering (IPO)certainly doesn't match the investment style of the legendary nonagenarian. In fact, Buffett hasn't bought an IPO since<b>Ford</b> in 1956. The company does fit the style of Cathie Wood at ARK Invest, a global asset management company focused on disruptive innovation. That said, Snowflake is putting up numbers that would get any investor's attention.</p><p><blockquote>首先,沃伦·巴菲特是否真的购买了股票值得怀疑<b>雪花</b>(纽约证券交易所代码:SNOW),云数据仓库即服务公司。近年来,托德·库姆斯中尉和特德·韦施勒中尉做出了更多的投资决策,以及价值 7.5 亿美元的股票<b>伯克希尔哈撒韦公司</b>(纽约证券交易所股票代码:BRK.A)(纽约证券交易所股票代码:BRK.B)在首次公开募股(IPO)之前购买的当然不符合这位传奇九十多岁老人的投资风格。事实上,巴菲特自那以后就再也没有买过 IPO<b>福特</b>1956年。该公司确实符合 ARK Invest 的凯西·伍德 (Cathie Wood) 的风格,ARK Invest 是一家专注于颠覆性创新的全球资产管理公司。也就是说,Snowflake 公布的数据会引起任何投资者的注意。</blockquote></p><p>The company recently reported its full fiscal year earnings, and the growth was jaw-dropping. Fourth-quarter revenue of $178 million was up 116% year over year. Topping that, remaining performance obligations, what customers have signed on to buy, was up 213% over the same point last year. The company has 77 customers that spend more than $1 million per year. That number is up from 65 just three months earlier. Management is projecting between 92% and 96% revenue growth for the current year. Snowflake posted an operating margin of negative 92%. Losing money never sounds good, but that is closer to profitability than the negative 135% for the year ending January 2020 or the negative 192% in 2019. If the company really wanted to turn a profit it could just curb its spending on sales and marketing.</p><p><blockquote>该公司最近公布了整个财年的收益,增长令人瞠目结舌。第四季度收入为 1.78 亿美元,同比增长 116%。最重要的是,客户签约购买的剩余履约义务比去年同期增长了 213%。该公司有77家每年消费超过100万美元的客户。这个数字高于三个月前的 65 个。管理层预计本年度收入增长 92% 至 96%。雪花公布的营业利润率为负92%。亏损听起来从来都不是好事,但这比截至2020年1月的负135%或2019年的负192%更接近盈利。如果该公司真的想盈利,它可以限制销售和营销支出。</blockquote></p><p>It may not be a typical Buffett stock, but Snowflake definitely fits the mold of Wood's investments. The ARK founder has become synonymous with innovation, building a portfolio around futuristic themes such as genomics, space exploration, mobility-as-a-service, and the next-generation internet. It's the last theme, encompassing artificial intelligence and cloud computing, where Snowflake fits. The company's pay-as-you-consume, real-time access to data and analytical tools is a giant leap forward compared to the slow, bogged-down daily or weekly updates companies have long come to accept with managing their internal data warehouses.</p><p><blockquote>它可能不是典型的巴菲特股票,但雪花绝对符合伍德的投资模式。方舟创始人已经成为创新的代名词,围绕基因组学、太空探索、移动即服务和下一代互联网等未来主题建立了一个产品组合。这是雪花适合的最后一个主题,包括人工智能和云计算。与公司长期以来在管理内部数据仓库时接受的缓慢、停滞不前的每日或每周更新相比,该公司的按需付费、实时访问数据和分析工具是一个巨大的飞跃。</blockquote></p><p>Another stock in ARK's portfolio touches both the data-related and genomic revolution strategy. Based on his other holdings, it's actually surprising Buffett doesn't own it too.</p><p><blockquote>ARK 投资组合中的另一只股票涉及数据相关和基因组革命战略。根据他的其他持股,巴菲特并不拥有它实际上令人惊讶。</blockquote></p><p><b>The surprising stock they don't both own</b></p><p><blockquote><b>他们都不拥有的令人惊讶的股票</b></blockquote></p><p>The Oracle of Omaha has been buying up the stocks of pharmaceutical companies in the past year. In the third quarter of 2020 he added shares of<b>Pfizer</b>(NYSE:PFE),<b>AbbVie</b>(NYSE:ABBV),<b>Merck</b>(NYSE:MRK), and<b>BristolMyersSquibb</b>(NYSE:BMY). Every member of that group gives investors between 3% and 5% in dividends annually. Other than Bristol Myers, they all hover around a $200 billion market cap as well, and Bristol Myers is nearly as large at $136 billion. Similarly,<b>Novartis</b>(NYSE:NVS)is a $211 billion company yielding 3.8%. Perhaps the reason Buffett hasn't bought this big pharma stock is that it is a Swiss company. It turns out, Buffett favors American brands in food, cola, and apparently drugmakers.</p><p><blockquote>奥马哈先知在过去的一年里一直在买入制药公司的股票。2020年第三季度,他增持了<b>辉瑞</b>(纽约证券交易所代码:PFE),<b>艾伯维</b>(纽约证券交易所代码:ABBV),<b>默克</b>(纽约证券交易所代码:MRK),以及<b>百时美施贵宝</b>(纽约证券交易所代码:BMY)。该集团的每个成员每年向投资者支付 3% 至 5% 的股息。除了百时美尔斯之外,它们的市值也都徘徊在 2000 亿美元左右,百时美尔斯的市值几乎相同,为 1360 亿美元。同样,<b>诺华</b>(纽约证券交易所股票代码:NVS)是一家市值 2110 亿美元的公司,收益率为 3.8%。也许巴菲特没有买入这只大型制药股票的原因是它是一家瑞士公司。事实证明,巴菲特青睐美国食品品牌、可乐,显然还有制药商。</blockquote></p><p>Novartis did catch the eye of Wood, thanks to its work toward developing a leading digital and data science platform for drug discovery. Although it isn't a pure play on any of ARK's strategies, Wood considers it a deep value pick, to be held through a bull market and then sold in times of volatility to add to higher-conviction growth names that get beaten down.</p><p><blockquote>诺华确实引起了伍德的注意,这要归功于其致力于开发领先的药物发现数字和数据科学平台。尽管这并不是对 ARK 任何策略的纯粹玩法,但伍德认为这是一个具有深度价值的选择,可以在牛市中持有,然后在波动时期出售,以增加那些被击败的信念更高的成长型股票。</blockquote></p><p><b>Portfolio juxtaposition</b></p><p><blockquote><b>组合并置</b></blockquote></p><p>It may be counterintuitive for an investor who prides himself on unemotional investing to buy into one of the hottest IPOs of last year, but once Snowflake started trading, the investment doubled almost immediately. Similarly, few would think someone famous for a $4,000 price target on<b>Tesla</b>and presentations that literally map out the future of entire industries would own a nearly 4% dividend paying pharmaceutical company with no growth. However, there is a great lesson in these examples.</p><p><blockquote>对于一个以不带感情的投资为荣的投资者来说,购买去年最热门的 IPO 之一可能是违反直觉的,但一旦 Snowflake 开始交易,投资几乎立即翻了一番。同样,很少有人会认为有人以 4,000 美元的目标价而闻名<b>特斯拉</b>从字面上描绘整个行业未来的演示文稿将拥有一家支付近 4% 股息但没有增长的制药公司。然而,这些例子中有一个很好的教训。</blockquote></p><p></p><p>Don't settle for the labels Wall Street places on companies or investors. Value and growth are just words. Investors may have tendencies that define them in the public eye, but that oversimplification may obscure the characteristics that draw their interest in an investment. Although Buffett likely didn't buy shares of Snowflake, it may have been the customer loyalty, leadership team, and consistent march toward profitability that made Combs or Weschler comfortable buying Snowflake shares. Wood may have a lot of fast-growing companies that don't make a profit, but it's the innovation that compels her to invest, not just growth rate. In the case of Novartis, innovation came in the form of a mega-cap pharmaceutical company.</p><p><blockquote>不要满足于华尔街给公司或投资者贴上的标签。价值和增长只是文字。投资者可能有在公众眼中定义他们的倾向,但这种过度简化可能会掩盖吸引他们对投资兴趣的特征。尽管巴菲特可能没有购买 Snowflake 的股票,但可能是客户忠诚度、领导团队以及持续的盈利能力让库姆斯或韦施勒对购买 Snowflake 股票感到满意。伍德可能有很多快速增长的公司没有盈利,但迫使她投资的是创新,而不仅仅是增长率。就诺华而言,创新是以大型制药公司的形式出现的。</blockquote></p><p>Instead of focusing on the labels Wall Street slaps on a company or following Warren Buffett or Cathie Wood into the stock, try to identify the characteristics of the business that they find compelling. Try approaching the company as if you were going to inherit it, learning how dedicated customers are, where money gets spent to attract new ones, or what advantages it has over competitors. These answers will lead to a more informed investment decision and better outcomes over time.</p><p><blockquote>不要关注华尔街给一家公司贴上的标签,也不要追随沃伦·巴菲特或凯西·伍德的股票,而是尝试找出他们认为引人注目的业务特征。尝试像要继承公司一样接近它,了解客户有多忠诚,资金花在哪里来吸引新客户,或者它相对于竞争对手有什么优势。随着时间的推移,这些答案将导致更明智的投资决策和更好的结果。</blockquote></p><p>It turns out, both Snowflake and Novartis are compelling to different types of investors for a variety of reasons. Exploring those reasons can teach us a lot more about investing than focusing solely on who owns them. The more we know about a company, the easier it is to figure out whether the nextsell-off is something to fear or a great opportunity.</p><p><blockquote>事实证明,由于各种原因,雪花和诺华都对不同类型的投资者具有吸引力。探索这些原因可以教会我们更多关于投资的知识,而不仅仅是关注谁拥有它们。我们对一家公司了解得越多,就越容易弄清楚下一次抛售是令人恐惧的事情还是一个绝佳的机会。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should<blockquote>沃伦·巴菲特和凯西·伍德拥有 1 只共同点,以及他们应该拥有的 1 只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should<blockquote>沃伦·巴菲特和凯西·伍德拥有 1 只共同点,以及他们应该拥有的 1 只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-03-19 21:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her outlandishly bullish (and accurate) predictions about \"overvalued\" stocks -- would have the same company in their portfolios. Perhaps the bigger surprise is the stock you might expect them to both own that they don't. Let's take a look at the two companies in question and what these successful investors must see.</p><p><blockquote>人们可能会惊讶地发现,两位持有几乎相反方法的投资者——一位投资于大型、廉价、标志性公司,另一位则因她对“高估”股票的异常乐观(且准确)预测而声名鹊起——他们的投资组合中将有同一家公司。也许更大的惊喜是你可能期望他们都拥有但他们没有的股票。让我们来看看这两家公司,以及这些成功的投资者必须看到什么。</blockquote></p><p><b>The surprising stock they both own</b></p><p><blockquote><b>他们都拥有令人惊讶的股票</b></blockquote></p><p>First, it's doubtful that Warren Buffett actually bought<b>Snowflake</b>(NYSE:SNOW), the cloud data warehouse-as-a-service company. In recent years, lieutenants Todd Combs and Ted Weschler have been making more of the investment decisions, and the $750 million in stock<b>BerkshireHathaway</b>(NYSE:BRK.A)(NYSE:BRK.B)purchased before theinitial public offering (IPO)certainly doesn't match the investment style of the legendary nonagenarian. In fact, Buffett hasn't bought an IPO since<b>Ford</b> in 1956. The company does fit the style of Cathie Wood at ARK Invest, a global asset management company focused on disruptive innovation. That said, Snowflake is putting up numbers that would get any investor's attention.</p><p><blockquote>首先,沃伦·巴菲特是否真的购买了股票值得怀疑<b>雪花</b>(纽约证券交易所代码:SNOW),云数据仓库即服务公司。近年来,托德·库姆斯中尉和特德·韦施勒中尉做出了更多的投资决策,以及价值 7.5 亿美元的股票<b>伯克希尔哈撒韦公司</b>(纽约证券交易所股票代码:BRK.A)(纽约证券交易所股票代码:BRK.B)在首次公开募股(IPO)之前购买的当然不符合这位传奇九十多岁老人的投资风格。事实上,巴菲特自那以后就再也没有买过 IPO<b>福特</b>1956年。该公司确实符合 ARK Invest 的凯西·伍德 (Cathie Wood) 的风格,ARK Invest 是一家专注于颠覆性创新的全球资产管理公司。也就是说,Snowflake 公布的数据会引起任何投资者的注意。</blockquote></p><p>The company recently reported its full fiscal year earnings, and the growth was jaw-dropping. Fourth-quarter revenue of $178 million was up 116% year over year. Topping that, remaining performance obligations, what customers have signed on to buy, was up 213% over the same point last year. The company has 77 customers that spend more than $1 million per year. That number is up from 65 just three months earlier. Management is projecting between 92% and 96% revenue growth for the current year. Snowflake posted an operating margin of negative 92%. Losing money never sounds good, but that is closer to profitability than the negative 135% for the year ending January 2020 or the negative 192% in 2019. If the company really wanted to turn a profit it could just curb its spending on sales and marketing.</p><p><blockquote>该公司最近公布了整个财年的收益,增长令人瞠目结舌。第四季度收入为 1.78 亿美元,同比增长 116%。最重要的是,客户签约购买的剩余履约义务比去年同期增长了 213%。该公司有77家每年消费超过100万美元的客户。这个数字高于三个月前的 65 个。管理层预计本年度收入增长 92% 至 96%。雪花公布的营业利润率为负92%。亏损听起来从来都不是好事,但这比截至2020年1月的负135%或2019年的负192%更接近盈利。如果该公司真的想盈利,它可以限制销售和营销支出。</blockquote></p><p>It may not be a typical Buffett stock, but Snowflake definitely fits the mold of Wood's investments. The ARK founder has become synonymous with innovation, building a portfolio around futuristic themes such as genomics, space exploration, mobility-as-a-service, and the next-generation internet. It's the last theme, encompassing artificial intelligence and cloud computing, where Snowflake fits. The company's pay-as-you-consume, real-time access to data and analytical tools is a giant leap forward compared to the slow, bogged-down daily or weekly updates companies have long come to accept with managing their internal data warehouses.</p><p><blockquote>它可能不是典型的巴菲特股票,但雪花绝对符合伍德的投资模式。方舟创始人已经成为创新的代名词,围绕基因组学、太空探索、移动即服务和下一代互联网等未来主题建立了一个产品组合。这是雪花适合的最后一个主题,包括人工智能和云计算。与公司长期以来在管理内部数据仓库时接受的缓慢、停滞不前的每日或每周更新相比,该公司的按需付费、实时访问数据和分析工具是一个巨大的飞跃。</blockquote></p><p>Another stock in ARK's portfolio touches both the data-related and genomic revolution strategy. Based on his other holdings, it's actually surprising Buffett doesn't own it too.</p><p><blockquote>ARK 投资组合中的另一只股票涉及数据相关和基因组革命战略。根据他的其他持股,巴菲特并不拥有它实际上令人惊讶。</blockquote></p><p><b>The surprising stock they don't both own</b></p><p><blockquote><b>他们都不拥有的令人惊讶的股票</b></blockquote></p><p>The Oracle of Omaha has been buying up the stocks of pharmaceutical companies in the past year. In the third quarter of 2020 he added shares of<b>Pfizer</b>(NYSE:PFE),<b>AbbVie</b>(NYSE:ABBV),<b>Merck</b>(NYSE:MRK), and<b>BristolMyersSquibb</b>(NYSE:BMY). Every member of that group gives investors between 3% and 5% in dividends annually. Other than Bristol Myers, they all hover around a $200 billion market cap as well, and Bristol Myers is nearly as large at $136 billion. Similarly,<b>Novartis</b>(NYSE:NVS)is a $211 billion company yielding 3.8%. Perhaps the reason Buffett hasn't bought this big pharma stock is that it is a Swiss company. It turns out, Buffett favors American brands in food, cola, and apparently drugmakers.</p><p><blockquote>奥马哈先知在过去的一年里一直在买入制药公司的股票。2020年第三季度,他增持了<b>辉瑞</b>(纽约证券交易所代码:PFE),<b>艾伯维</b>(纽约证券交易所代码:ABBV),<b>默克</b>(纽约证券交易所代码:MRK),以及<b>百时美施贵宝</b>(纽约证券交易所代码:BMY)。该集团的每个成员每年向投资者支付 3% 至 5% 的股息。除了百时美尔斯之外,它们的市值也都徘徊在 2000 亿美元左右,百时美尔斯的市值几乎相同,为 1360 亿美元。同样,<b>诺华</b>(纽约证券交易所股票代码:NVS)是一家市值 2110 亿美元的公司,收益率为 3.8%。也许巴菲特没有买入这只大型制药股票的原因是它是一家瑞士公司。事实证明,巴菲特青睐美国食品品牌、可乐,显然还有制药商。</blockquote></p><p>Novartis did catch the eye of Wood, thanks to its work toward developing a leading digital and data science platform for drug discovery. Although it isn't a pure play on any of ARK's strategies, Wood considers it a deep value pick, to be held through a bull market and then sold in times of volatility to add to higher-conviction growth names that get beaten down.</p><p><blockquote>诺华确实引起了伍德的注意,这要归功于其致力于开发领先的药物发现数字和数据科学平台。尽管这并不是对 ARK 任何策略的纯粹玩法,但伍德认为这是一个具有深度价值的选择,可以在牛市中持有,然后在波动时期出售,以增加那些被击败的信念更高的成长型股票。</blockquote></p><p><b>Portfolio juxtaposition</b></p><p><blockquote><b>组合并置</b></blockquote></p><p>It may be counterintuitive for an investor who prides himself on unemotional investing to buy into one of the hottest IPOs of last year, but once Snowflake started trading, the investment doubled almost immediately. Similarly, few would think someone famous for a $4,000 price target on<b>Tesla</b>and presentations that literally map out the future of entire industries would own a nearly 4% dividend paying pharmaceutical company with no growth. However, there is a great lesson in these examples.</p><p><blockquote>对于一个以不带感情的投资为荣的投资者来说,购买去年最热门的 IPO 之一可能是违反直觉的,但一旦 Snowflake 开始交易,投资几乎立即翻了一番。同样,很少有人会认为有人以 4,000 美元的目标价而闻名<b>特斯拉</b>从字面上描绘整个行业未来的演示文稿将拥有一家支付近 4% 股息但没有增长的制药公司。然而,这些例子中有一个很好的教训。</blockquote></p><p></p><p>Don't settle for the labels Wall Street places on companies or investors. Value and growth are just words. Investors may have tendencies that define them in the public eye, but that oversimplification may obscure the characteristics that draw their interest in an investment. Although Buffett likely didn't buy shares of Snowflake, it may have been the customer loyalty, leadership team, and consistent march toward profitability that made Combs or Weschler comfortable buying Snowflake shares. Wood may have a lot of fast-growing companies that don't make a profit, but it's the innovation that compels her to invest, not just growth rate. In the case of Novartis, innovation came in the form of a mega-cap pharmaceutical company.</p><p><blockquote>不要满足于华尔街给公司或投资者贴上的标签。价值和增长只是文字。投资者可能有在公众眼中定义他们的倾向,但这种过度简化可能会掩盖吸引他们对投资兴趣的特征。尽管巴菲特可能没有购买 Snowflake 的股票,但可能是客户忠诚度、领导团队以及持续的盈利能力让库姆斯或韦施勒对购买 Snowflake 股票感到满意。伍德可能有很多快速增长的公司没有盈利,但迫使她投资的是创新,而不仅仅是增长率。就诺华而言,创新是以大型制药公司的形式出现的。</blockquote></p><p>Instead of focusing on the labels Wall Street slaps on a company or following Warren Buffett or Cathie Wood into the stock, try to identify the characteristics of the business that they find compelling. Try approaching the company as if you were going to inherit it, learning how dedicated customers are, where money gets spent to attract new ones, or what advantages it has over competitors. These answers will lead to a more informed investment decision and better outcomes over time.</p><p><blockquote>不要关注华尔街给一家公司贴上的标签,也不要追随沃伦·巴菲特或凯西·伍德的股票,而是尝试找出他们认为引人注目的业务特征。尝试像要继承公司一样接近它,了解客户有多忠诚,资金花在哪里来吸引新客户,或者它相对于竞争对手有什么优势。随着时间的推移,这些答案将导致更明智的投资决策和更好的结果。</blockquote></p><p>It turns out, both Snowflake and Novartis are compelling to different types of investors for a variety of reasons. Exploring those reasons can teach us a lot more about investing than focusing solely on who owns them. The more we know about a company, the easier it is to figure out whether the nextsell-off is something to fear or a great opportunity.</p><p><blockquote>事实证明,由于各种原因,雪花和诺华都对不同类型的投资者具有吸引力。探索这些原因可以教会我们更多关于投资的知识,而不仅仅是关注谁拥有它们。我们对一家公司了解得越多,就越容易弄清楚下一次抛售是令人恐惧的事情还是一个绝佳的机会。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://www.fool.com/investing/2021/03/19/1-stock-warren-buffett-and-cathie-wood-have-in-com/\">Motley Fool</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/19/1-stock-warren-buffett-and-cathie-wood-have-in-com/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190757715","content_text":"It might be a surprise to find out that two investors with virtually opposite approaches -- one who invests in large, cheap, iconic companies and the other who rose to fame on the heels of her outlandishly bullish (and accurate) predictions about \"overvalued\" stocks -- would have the same company in their portfolios. Perhaps the bigger surprise is the stock you might expect them to both own that they don't. Let's take a look at the two companies in question and what these successful investors must see.The surprising stock they both ownFirst, it's doubtful that Warren Buffett actually boughtSnowflake(NYSE:SNOW), the cloud data warehouse-as-a-service company. In recent years, lieutenants Todd Combs and Ted Weschler have been making more of the investment decisions, and the $750 million in stockBerkshireHathaway(NYSE:BRK.A)(NYSE:BRK.B)purchased before theinitial public offering (IPO)certainly doesn't match the investment style of the legendary nonagenarian. In fact, Buffett hasn't bought an IPO sinceFord in 1956. The company does fit the style of Cathie Wood at ARK Invest, a global asset management company focused on disruptive innovation. That said, Snowflake is putting up numbers that would get any investor's attention.The company recently reported its full fiscal year earnings, and the growth was jaw-dropping. Fourth-quarter revenue of $178 million was up 116% year over year. Topping that, remaining performance obligations, what customers have signed on to buy, was up 213% over the same point last year. The company has 77 customers that spend more than $1 million per year. That number is up from 65 just three months earlier. Management is projecting between 92% and 96% revenue growth for the current year. Snowflake posted an operating margin of negative 92%. Losing money never sounds good, but that is closer to profitability than the negative 135% for the year ending January 2020 or the negative 192% in 2019. If the company really wanted to turn a profit it could just curb its spending on sales and marketing.It may not be a typical Buffett stock, but Snowflake definitely fits the mold of Wood's investments. The ARK founder has become synonymous with innovation, building a portfolio around futuristic themes such as genomics, space exploration, mobility-as-a-service, and the next-generation internet. It's the last theme, encompassing artificial intelligence and cloud computing, where Snowflake fits. The company's pay-as-you-consume, real-time access to data and analytical tools is a giant leap forward compared to the slow, bogged-down daily or weekly updates companies have long come to accept with managing their internal data warehouses.Another stock in ARK's portfolio touches both the data-related and genomic revolution strategy. Based on his other holdings, it's actually surprising Buffett doesn't own it too.The surprising stock they don't both ownThe Oracle of Omaha has been buying up the stocks of pharmaceutical companies in the past year. In the third quarter of 2020 he added shares ofPfizer(NYSE:PFE),AbbVie(NYSE:ABBV),Merck(NYSE:MRK), andBristolMyersSquibb(NYSE:BMY). Every member of that group gives investors between 3% and 5% in dividends annually. Other than Bristol Myers, they all hover around a $200 billion market cap as well, and Bristol Myers is nearly as large at $136 billion. Similarly,Novartis(NYSE:NVS)is a $211 billion company yielding 3.8%. Perhaps the reason Buffett hasn't bought this big pharma stock is that it is a Swiss company. It turns out, Buffett favors American brands in food, cola, and apparently drugmakers.Novartis did catch the eye of Wood, thanks to its work toward developing a leading digital and data science platform for drug discovery. Although it isn't a pure play on any of ARK's strategies, Wood considers it a deep value pick, to be held through a bull market and then sold in times of volatility to add to higher-conviction growth names that get beaten down.Portfolio juxtapositionIt may be counterintuitive for an investor who prides himself on unemotional investing to buy into one of the hottest IPOs of last year, but once Snowflake started trading, the investment doubled almost immediately. Similarly, few would think someone famous for a $4,000 price target onTeslaand presentations that literally map out the future of entire industries would own a nearly 4% dividend paying pharmaceutical company with no growth. However, there is a great lesson in these examples.Don't settle for the labels Wall Street places on companies or investors. Value and growth are just words. Investors may have tendencies that define them in the public eye, but that oversimplification may obscure the characteristics that draw their interest in an investment. Although Buffett likely didn't buy shares of Snowflake, it may have been the customer loyalty, leadership team, and consistent march toward profitability that made Combs or Weschler comfortable buying Snowflake shares. Wood may have a lot of fast-growing companies that don't make a profit, but it's the innovation that compels her to invest, not just growth rate. In the case of Novartis, innovation came in the form of a mega-cap pharmaceutical company.Instead of focusing on the labels Wall Street slaps on a company or following Warren Buffett or Cathie Wood into the stock, try to identify the characteristics of the business that they find compelling. Try approaching the company as if you were going to inherit it, learning how dedicated customers are, where money gets spent to attract new ones, or what advantages it has over competitors. These answers will lead to a more informed investment decision and better outcomes over time.It turns out, both Snowflake and Novartis are compelling to different types of investors for a variety of reasons. Exploring those reasons can teach us a lot more about investing than focusing solely on who owns them. The more we know about a company, the easier it is to figure out whether the nextsell-off is something to fear or a great opportunity.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1097,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":33,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/359959063"}
精彩评论